|Bid||74.00 x 1000|
|Ask||77.11 x 1300|
|Day's range||76.31 - 82.86|
|52-week range||21.19 - 86.05|
|Beta (5Y monthly)||1.97|
|PE ratio (TTM)||87.70|
|Earnings date||04 Feb 2021 - 08 Feb 2021|
|Forward dividend & yield||0.40 (0.52%)|
|Ex-dividend date||03 Dec 2020|
|1y target est||82.29|
Brooks Automation, Inc. (Nasdaq: BRKS) will announce fiscal 2021 first quarter which ended on December 31, 2020 on Tuesday, February 2, 2021 after the market closes.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company's genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI). The NCI, the nation's leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to provide whole exome sequencing to new research projects at its Center for Cancer Genomics for a period of three years.